Lenz Therapeutics Inc (LENZ) Stock Price, Quote & News

Company Profile

LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.

Industry: Biotechnology

Sector: Healthcare

Phone: 858 925 7000

Website: www.lenz-tx.com

Address:

201 Lomas Santa Fe Drive, Suite 300, Solana Beach, United States

Sergey_stockdoc Jul. 1 at 11:53 AM

$LENZ All I can say is good luck short sellers…

0 · Reply

JRobb66 Jul. 1 at 11:45 AM

$LENZ man oh man I fucked myself buying into this … I started at $21 and kept buying alllll the way down. Leveraged and dying in this crap

0 · Reply

TickrTalk0007 Jun. 29 at 7:25 PM

$LENZ this company should have never been public...it was RA Capital's stupid bet and they kept throwing money at it to rescue themselves.... now they are in Memento and will do the same. They need to be banned from using public markets as an exit for their companies that no pharma wants to buy

0 · Reply

TickrTalk0007 Jun. 29 at 2:23 PM

$NVDA $SPY this company $LENZ is trading at $5.56...$5 put options selling for $0.10 lol

0 · Reply

Max_Regards Jun. 29 at 1:32 PM

$LENZ so much pain, I have been upgraded to long term investor lmao 😭

2 · Reply

Monty3030 Jun. 26 at 9:27 PM

$LENZ 14.42 days to cover 70.02% short interest

0 · Reply

Dreamit2 Jun. 26 at 2:21 PM

$LENZ Insiders have been buying again. Believe they know the value of their company.

2 · Reply

TickrTalk0007 Jun. 26 at 2:17 AM

$LENZ well and you will thank me

0 · Reply

Dreamit2 Jun. 25 at 6:48 PM

$LENZ Trading well below book value now. Somebody might do a hostile takeover.

1 · Reply

Dreamit2 Jun. 24 at 7:51 PM

$LENZ Worldwide sales could easily top the market cap. And at eighty percent profit margin shorts are playing with fire.

3 · Reply

LENZ Therapeutics and Arrotex Pharmaceuticals Announce Exclusive License and Commercialization Agreement for VIZZ™ in Australia and New Zealand

2026-06-08T01:10:06.000Z - 23 days ago

Lenz announces Everest Medicines acquired rights to develop VIZZ in China

Jun 7, 2026, 7:30 PM EDT - 23 days ago

LENZ Therapeutics Announces Everest Medicines Acquired Rights to Develop and Commercialize VIZZ® (LNZ100) in Greater China

May 26, 2026, 8:00 AM EDT - 5 weeks ago

LENZ Therapeutics to Participate in Upcoming Investor Conferences

2026-05-13T10:43:53.000Z - 7 weeks ago

Lenz Therapeutics price target lowered to $20 from $26 at Citi

2026-05-12T19:26:31.000Z - 7 weeks ago

LENZ Therapeutics trading halted, volatility trading pause

2026-05-12T19:21:07.000Z - 7 weeks ago

LENZ Therapeutics trading resumes

2026-05-12T14:13:30.000Z - 7 weeks ago

Lenz Therapeutics price target raised to $31 from $29 at BofA

2026-05-12T10:17:53.000Z - 7 weeks ago

Lenz Therapeutics price target lowered to $38 from $48 at H.C. Wainwright

2026-05-12T09:16:13.000Z - 7 weeks ago

Lenz Therapeutics downgraded to Neutral from Overweight at Piper Sandler

2026-05-11T23:50:20.000Z - 7 weeks ago

Lenz Therapeutics reports Q1 EPS ($1.32), consensus ($1.07)

May 11, 2026, 4:30 PM EDT - 7 weeks ago

LENZ Therapeutics Earnings Call Transcript: Q1 2026

May 11, 2026, 4:30 PM EDT - 7 weeks ago

LENZ Therapeutics Earnings release: Q1 2026

May 11, 2026, 4:30 PM EDT - 7 weeks ago

LENZ Therapeutics Quarterly report: Q1 2026

May 11, 2026, 4:05 PM EDT - 7 weeks ago

LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

May 4, 2026, 8:00 AM EDT - 2 months ago

LENZ Therapeutics to Report First Quarter 2026 Financial Results and Recent Corporate Highlights on May 11, 2026 and Attend Upcoming Investor Conference

Apr 28, 2026, 8:00 AM EDT - 2 months ago

LENZ Therapeutics Proxy statement: Proxy filing

Apr 28, 2026, 8:00 AM EDT - 2 months ago

LENZ Therapeutics Proxy statement: Proxy filing

2026-04-21T10:11:58.000Z - 2 months ago

Lenz Therapeutics price target lowered to $48 from $56 at H.C. Wainwright

2026-04-20T12:56:52.000Z - 2 months ago

Lenz Therapeutics announces submission of MAA to U.K.’s MHRA for VIZZ 1.44%

Apr 20, 2026, 8:00 AM EDT - 2 months ago

LENZ Therapeutics Announces Submission of Marketing Authorization Application to the Medicines and Healthcare products Regulatory Agency for VIZZ® for the Treatment of Presbyopia in the United Kingdom

2026-03-26T10:31:04.000Z - 3 months ago

Lenz Therapeutics price target lowered to $26 from $52 at Citi

2026-03-25T11:22:03.000Z - 3 months ago

Lenz Therapeutics price target lowered to $29 from $35 at BofA

Mar 24, 2026, 8:30 AM EDT - 3 months ago

LENZ Therapeutics Earnings Call Transcript: Q4 2025

Mar 24, 2026, 8:30 AM EDT - 3 months ago

LENZ Therapeutics Annual report: Q4 2025

Mar 24, 2026, 8:30 AM EDT - 3 months ago

LENZ Therapeutics Earnings release: Q4 2025

2026-03-24T12:16:56.000Z - 3 months ago

Lenz Therapeutics reports Q4 EPS ($1.16), consensus (90c)

Mar 24, 2026, 8:00 AM EDT - 3 months ago

LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

Mar 17, 2026, 8:00 AM EDT - 3 months ago

LENZ Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights on March 24, 2026

Mar 10, 2026, 10:00 AM EDT - 4 months ago

LENZ Therapeutics Transcript: Leerink Global Healthcare Conference 2026

2026-03-10T12:38:41.000Z - 4 months ago

Lenz Therapeutics announces submission of MAA to EMA for VIZ

Mar 10, 2026, 8:00 AM EDT - 4 months ago

LENZ Therapeutics Announces Submission of Marketing Authorization Application to European Medicines Agency for VIZZ® for the Treatment of Presbyopia

Mar 2, 2026, 9:50 AM EST - 4 months ago

LENZ Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 7:00 AM EST - 4 months ago

LENZ Therapeutics Slides: Corporate presentation

Feb 23, 2026, 8:00 AM EST - 4 months ago

LENZ Therapeutics to Present at Upcoming Investor Conferences

2026-02-19T20:55:33.000Z - 4 months ago

Citi says buy Lenz Therapeutics on ‘FAERS induced’ selloff

Jan 14, 2026, 8:30 AM EST - 6 months ago

LENZ Therapeutics and Sarah Jessica Parker announce the launch of “Make it VIZZable”, the VIZZ consumer campaign

Jan 7, 2026, 5:08 PM EST - 6 months ago

LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates

Jan 5, 2026, 8:00 AM EST - 6 months ago

LENZ Therapeutics and Lunatus Announce Exclusive Commercialization Partnership for VIZZ™ in the Middle East

Dec 4, 2025, 10:30 AM EST - 7 months ago

LENZ Therapeutics Transcript: Citi Annual Global Healthcare Conference 2025

Dec 3, 2025, 1:20 PM EST - 7 months ago

LENZ Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 3:30 PM EST - 7 months ago

LENZ Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 1, 2025, 8:30 AM EST - 7 months ago

LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia

Nov 5, 2025, 8:30 AM EST - 8 months ago

LENZ Therapeutics Earnings Call Transcript: Q3 2025

Nov 5, 2025, 8:30 AM EST - 8 months ago

LENZ Therapeutics Earnings release: Q3 2025

Nov 5, 2025, 8:00 AM EST - 8 months ago

LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

Nov 4, 2025, 6:00 PM EST - 8 months ago

LENZ Therapeutics Slides: Corporate Presentation

Oct 29, 2025, 8:00 AM EDT - 8 months ago

LENZ Therapeutics to Report Third Quarter 2025 Financial Results and Recent Corporate Highlights on November 5, 2025

Sep 30, 2025, 8:05 AM EDT - 9 months ago

LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States

Sep 30, 2025, 8:00 AM EDT - 9 months ago

LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States

Sep 10, 2025, 10:00 AM EDT - 10 months ago

LENZ Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 9, 2025, 11:00 AM EDT - 10 months ago

LENZ Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 4, 2025, 1:45 PM EDT - 10 months ago

LENZ Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 9:45 AM EDT - 10 months ago

LENZ Therapeutics Transcript: Citi's Biopharma Back to School Conference

Aug 25, 2025, 8:00 AM EDT - 11 months ago

LENZ Therapeutics to Present at Upcoming Investor and Medical Conferences

Aug 1, 2025, 8:00 AM EDT - 11 months ago

LENZ Therapeutics Transcript: Study Update

Aug 1, 2025, 8:00 AM EDT - 11 months ago

LENZ Therapeutics Press release: Study Update

Jul 31, 2025, 4:05 PM EDT - 11 months ago

LENZ Therapeutics Announces US FDA Approval of VIZZ™ for the Treatment of Presbyopia

Jul 30, 2025, 8:00 AM EDT - 1 year ago

LENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Jul 30, 2025, 8:00 AM EDT - 1 year ago

LENZ Therapeutics Quarterly report: Q2 2025

Jul 30, 2025, 8:00 AM EDT - 1 year ago

LENZ Therapeutics Earnings release: Q2 2025

Jul 28, 2025, 8:00 AM EDT - 1 year ago

LENZ Therapeutics Announces NMPA Submission of New Drug Application for LNZ100 in China for the Treatment of Presbyopia

Jul 7, 2025, 8:00 AM EDT - 1 year ago

LENZ Therapeutics and Laboratoires Théa Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada

Jun 9, 2025, 4:00 PM EDT - 1 year ago

LENZ Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

May 13, 2025, 12:20 PM EDT - 1 year ago

LENZ Therapeutics Transcript: BofA Securities 2025 Healthcare Conference

May 9, 2025, 9:03 AM EDT - 1 year ago

LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia

May 7, 2025, 4:30 PM EDT - 1 year ago

LENZ Therapeutics Earnings Call Transcript: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

LENZ Therapeutics Quarterly report: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

LENZ Therapeutics Earnings release: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

LENZ Therapeutics Slides: Q1 2025

May 7, 2025, 4:05 PM EDT - 1 year ago

LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 6, 2025, 4:30 PM EDT - 1 year ago

LENZ Therapeutics to Participate in Upcoming BofA Securities 2025 Health Care Conference

Apr 30, 2025, 4:30 PM EDT - 1 year ago

LENZ Therapeutics to Report First Quarter 2025 Financial Results and Recent Corporate Highlights on May 7th, 2025

Apr 15, 2025, 2:00 PM EDT - 1 year ago

LENZ Therapeutics Transcript: Status Update

Mar 19, 2025, 4:30 PM EDT - 1 year ago

LENZ Therapeutics Earnings Call Transcript: Q4 2024

Mar 19, 2025, 4:30 PM EDT - 1 year ago

LENZ Therapeutics Annual report: Q4 2024

Mar 19, 2025, 4:30 PM EDT - 1 year ago

LENZ Therapeutics Earnings release: Q4 2024

Mar 19, 2025, 4:30 PM EDT - 1 year ago

LENZ Therapeutics Slides: Q4 2024

Mar 19, 2025, 4:05 PM EDT - 1 year ago

LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

Mar 11, 2025, 8:00 AM EDT - 1 year ago

LENZ Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights on March 19, 2025

Mar 3, 2025, 9:50 AM EST - 1 year ago

LENZ Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 8:00 AM EST - 1 year ago

LENZ Therapeutics to Host Commercial Day on April 15, 2025

Dec 3, 2024, 3:30 PM EST - 1 year ago

LENZ Therapeutics Transcript: Piper Sandler 36th Annual Healthcare Conference

Nov 6, 2024, 8:00 AM EST - 1 year ago

LENZ Therapeutics Earnings Call Transcript: Q3 2024

Nov 6, 2024, 8:00 AM EST - 1 year ago

LENZ Therapeutics Quarterly report: Q3 2024

Nov 6, 2024, 8:00 AM EST - 1 year ago

LENZ Therapeutics Earnings release: Q3 2024

Nov 6, 2024, 8:00 AM EST - 1 year ago

LENZ Therapeutics Slides: Q3 2024

Oct 27, 2024, 9:00 PM EDT - 1 year ago

CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100

Oct 21, 2024, 8:00 AM EDT - 1 year ago

LENZ Therapeutics Announces FDA Acceptance of New Drug Application for LNZ100 for the Treatment of Presbyopia

Oct 15, 2024, 8:00 AM EDT - 1 year ago

Lucy Therapeutics Appoints Kim Drapkin as Board Chair

ABOS

Sep 18, 2024, 10:55 AM EDT - 1 year ago

LENZ Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Aug 14, 2024, 4:30 PM EDT - 2 years ago

LENZ Therapeutics Earnings Call Transcript: Q2 2024

Aug 14, 2024, 4:30 PM EDT - 2 years ago

LENZ Therapeutics Quarterly report: Q2 2024

Aug 14, 2024, 4:30 PM EDT - 2 years ago

LENZ Therapeutics Earnings release: Q2 2024

Aug 14, 2024, 4:05 PM EDT - 2 years ago

LENZ Therapeutics Reports Second Quarter 2024 Financial Results

Aug 12, 2024, 8:00 AM EDT - 2 years ago

LENZ Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for LNZ100 for the Treatment of Presbyopia

Aug 7, 2024, 4:01 PM EDT - 2 years ago

LENZ Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

Jun 18, 2024, 7:00 AM EDT - 2 years ago

LENZ Therapeutics Slides: KOL Event Presentation

Jun 13, 2024, 7:00 AM EDT - 2 years ago

LENZ Therapeutics Slides: Corporate Presentation

Jun 10, 2024, 8:00 AM EDT - 2 years ago

LENZ Therapeutics to Host Key Opinion Leader Event on June 18, 2024

May 30, 2024, 8:00 AM EDT - 2 years ago

LENZ Therapeutics to Present at the Jefferies Global Healthcare Conference

May 8, 2024, 4:01 PM EDT - 2 years ago

LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates

May 8, 2024, 4:00 PM EDT - 2 years ago

LENZ Therapeutics Earnings Call Transcript: Q1 2024

May 8, 2024, 4:00 PM EDT - 2 years ago

LENZ Therapeutics Quarterly report: Q1 2024

May 8, 2024, 4:00 PM EDT - 2 years ago

LENZ Therapeutics Earnings release: Q1 2024

May 1, 2024, 4:01 PM EDT - 2 years ago

LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024

Apr 3, 2024, 7:49 AM EDT - 2 years ago

Lenz Therapeutics' eye disease drugs meet main goal of late-stage study

Apr 3, 2024, 7:00 AM EDT - 2 years ago

LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials

Apr 3, 2024, 7:00 AM EDT - 2 years ago

LENZ Therapeutics Transcript: Study Result

Apr 3, 2024, 7:00 AM EDT - 2 years ago

LENZ Therapeutics Press release: Study Result

Apr 3, 2024, 7:00 AM EDT - 2 years ago

LENZ Therapeutics Slides: Study Result

Apr 2, 2024, 4:01 PM EDT - 2 years ago

LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials

Mar 21, 2024, 4:30 PM EDT - 2 years ago

LENZ Therapeutics Announces Completion of Merger with Graphite Bio and Provides Update on Recent Clinical and Corporate Progress

Sergey_stockdoc Jul. 1 at 11:53 AM

$LENZ All I can say is good luck short sellers…

0 · Reply

JRobb66 Jul. 1 at 11:45 AM

$LENZ man oh man I fucked myself buying into this … I started at $21 and kept buying alllll the way down. Leveraged and dying in this crap

0 · Reply

TickrTalk0007 Jun. 29 at 7:25 PM

0 · Reply

TickrTalk0007 Jun. 29 at 2:23 PM

$NVDA $SPY this company $LENZ is trading at $5.56...$5 put options selling for $0.10 lol

0 · Reply

Max_Regards Jun. 29 at 1:32 PM

$LENZ so much pain, I have been upgraded to long term investor lmao 😭

2 · Reply

Monty3030 Jun. 26 at 9:27 PM

$LENZ 14.42 days to cover 70.02% short interest

0 · Reply

Dreamit2 Jun. 26 at 2:21 PM

$LENZ Insiders have been buying again. Believe they know the value of their company.

2 · Reply

TickrTalk0007 Jun. 26 at 2:17 AM

$LENZ well and you will thank me

0 · Reply

Dreamit2 Jun. 25 at 6:48 PM

$LENZ Trading well below book value now. Somebody might do a hostile takeover.

1 · Reply

Dreamit2 Jun. 24 at 7:51 PM

$LENZ Worldwide sales could easily top the market cap. And at eighty percent profit margin shorts are playing with fire.

3 · Reply

pelle321 Jun. 23 at 4:53 AM

$LENZ

0 · Reply

TickrTalk0007 Jun. 22 at 8:08 PM

$LENZ post-earnings this will be sub $5.... really bad what RA Capital and Sequoia did to retail

1 · Reply

philipv777 Jun. 18 at 4:07 PM

$LENZ 😣 painful

1 · Reply

Brabbit1000 Jun. 18 at 2:07 PM

$LENZ if you haven’t been shorting this stock then you don’t like money. We will see $3-4 here soon.

5 · Reply

jGoooo Jun. 18 at 1:33 PM

$LENZ

0 · Reply

TickrTalk0007 Jun. 15 at 9:59 PM

$LENZ sales numbers are going to be very disappointing....also look at the SG&A expenses

2 · Reply

AngryElf Jun. 14 at 7:33 PM

$LENZ I know one person who will be listening ....

0 · Reply

PeterV9764 Jun. 11 at 10:48 PM

$LENZ I believe the shareholder meeting is broadcasted tomorrow 10 am PT. Does anyone think we will hear much on Vizz progress?

2 · Reply

AngryElf Jun. 11 at 9:46 PM

$LENZ All part of the evil plans of Mr. Pelicanman...

1 · Reply

aquira Jun. 11 at 3:15 PM

$LENZ dizzz turd dead?

0 · Reply

Brabbit1000 Jun. 11 at 3:11 PM

$LENZ I’ve been preaching since this stock was at $30, but I want to repeat that this couldn’t be more dead. Get out while you can. This drop market doesn’t exist. Please protect your money.

1 · Reply

PeterV9764 Jun. 10 at 3:51 PM

$LENZ Has anyone heard anything from these 1 on 1 meetings from mgmt? Too bad these were not broadcasted ? I assume because no real evidence of conviction from consumers yet on Vizz ?…… wait and see …

4 · Reply

Market Cap	180.60M
Revenue (ttm)	19.09M
Net Income (ttm)	-82.13M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-430.23%
Debt to Equity Ratio	0.00

Volume	1,183,900
Avg Vol	812,038
Day's Range	N/A - N/A
Shares Out	31.35M
Stochastic %K	28%
Beta	0.58
Analysts	Strong Sell
Price Target	$30.17